Noumegni Steve Raoul Ngongang, Nansseu Jobert Richie, Ama Vicky Jocelyne Moor, Bigna Jean Joel, Assah Felix Kembe, Guewo-Fokeng Magellan, Leumi Steve, Katte Jean-Claude, Dehayem Mesmin, Kengne Andre Pascal, Sobngwi Eugene
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 1364, Yaoundé, Cameroon.
Faculty of Medicine, University of Paris Sud XI, 63 Av Gabriel Péri, Le Kremlin Bicêtre, France.
Lipids Health Dis. 2017 Aug 10;16(1):148. doi: 10.1186/s12944-017-0543-1.
Little is known on the magnitude and correlates of insulin resistance in HIV-infected people in Africa. We determined the prevalence of insulin resistance and investigated associated factors in HIV-infected adult Cameroonians.
We conducted a cross-sectional study at the Yaoundé Central Hospital, Cameroon; during which we enrolled HIV-infected people aged 30 to 74 years with no previous history of cardiovascular disease. An homeostatic model assessment of insulin resistance (HOMA-IR) like index served to assess insulin sensitivity with insulin resistance defined by values of 2.1 or higher.
We included 452 patients (20% men). Their mean age was 44.4 ± 9.8 years and 88.5% of them were on antiretroviral therapy (93.3% on first line regimen including Zidovudine, lamivudine and Efavirenz/Nevirapine). Of all participants, 28.5% were overweight, 19.5% had obesity and 2.0% had diabetes. The prevalence of insulin resistance was 47.3% without any difference between patients on ART and those ART-naïve (48.5% vs. 38.5%; p = 0.480). Obesity was the only factor independently associated with insulin resistance (adjusted odds ratio: 2.28; 95% confidence interval: 1.10-4.72).
Insulin resistance is present in nearly half of HIV-infected patients in Cameroon despite a low prevalence rate of diabetes, and is associated with obesity.
在非洲,人们对艾滋病毒感染者胰岛素抵抗的程度及其相关因素了解甚少。我们测定了喀麦隆感染艾滋病毒的成年人中胰岛素抵抗的患病率,并调查了相关因素。
我们在喀麦隆雅温得中心医院进行了一项横断面研究;在此期间,我们纳入了年龄在30至74岁之间、既往无心血管疾病史的艾滋病毒感染者。采用一种类似胰岛素抵抗稳态模型评估(HOMA-IR)的指标来评估胰岛素敏感性,胰岛素抵抗定义为数值2.1及以上。
我们纳入了452名患者(20%为男性)。他们的平均年龄为44.4±9.8岁,其中88.5%正在接受抗逆转录病毒治疗(93.3%采用包括齐多夫定、拉米夫定和依非韦伦/奈韦拉平的一线治疗方案)。在所有参与者中,28.5%超重,19.5%肥胖,2.0%患有糖尿病。胰岛素抵抗的患病率为47.3%,接受抗逆转录病毒治疗的患者与未接受抗逆转录病毒治疗的患者之间无差异(48.5%对38.5%;p = 0.480)。肥胖是唯一与胰岛素抵抗独立相关的因素(调整后的优势比:2.28;95%置信区间:1.10 - 4.72)。
尽管糖尿病患病率较低,但喀麦隆近一半的艾滋病毒感染患者存在胰岛素抵抗,且与肥胖有关。